Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
NIH OI: Flucytosine
Product / population
Adults with HIV.
Renal method
NIH table: CrCl or eGFR; not interchangeable. Not CRRT.
Source revision
Updated April 23, 2025; reviewed March 16, 2026
Retrieved
2026-09-05
Local review status
Source-read local summary; source-specific recommendations are not automatically interchangeable.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Qualitative label versus institutional intervals; exactly 20 overlaps
ANCOBON emphasizes concentration-guided adjustment without a renal interval table. UCSF supplies intervals, but its printed 20-40 and 10-20 bands both include 20.
What to reconcile: Clarify the boundary and dosing weight with ID/pharmacy; retain serum-level and toxicity monitoring.
Renal method: NIH table: CrCl or eGFR; not interchangeable. Not CRRT. Source date: Updated April 23, 2025; reviewed March 16, 2026 Retrieved: 2026-09-05
Source-read local summary; source-specific recommendations are not automatically interchangeable.
Dose and kidney adjustment
Usual: 25 mg/kg orally every 6 hours. Renal estimate 21-40 / 10-20 / <10 mL/min: 25 mg/kg every 12 / 24 / 48 hours. Intermittent HD: 25-50 mg/kg every 48-72 hours after HD. Target two-hour peak: 25-100 mcg/mL; without drug-level monitoring, check CBC twice weekly.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.